Wednesday, March 3, 2021
  • About
  • Advertise
  • Careers
PRNewsCentre
  • Business
    • Business & Finance
    • Entertainment
    • General Business
    • Travel
    • Transportation
  • Internet
    • Blockchain
    • Data Analytics
    • Fintech
    • Internet Technology
    • Networks
  • Technology
    • Artificial Intelligence
    • Consumer Technology
    • Environment
    • Manufacturing
    • Telecommunications
  • Lifestyle
    • Entertainment
    • Fashion
    • Retail
    • Sports
    • Travel
  • Health
    • All Health
    • Biotechnology
    • Fitness
    • Pharmaceutical
    • Medical Equipment
  • Submit PR
No Result
View All Result
PRNewsCentre
Home Biotechnology

Sirnaomics to Present at Medical Dermatology Summit

PRNewsCentre by PRNewsCentre
February 2, 2021
in Biotechnology
0
0
Federated Hermes Premier Municipal Income Fund Declares Dividend
16
VIEWS
Share on LinkedinShare on Twitter

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Feb. 2, 2021 /PRNewsCentre/ — Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that it will be presenting results from a recently completed Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer, at the 19th Annual South Beach Symposium Medical Dermatology Summit. The virtual conference runs from Feb. 5-7, 2021.

  • Title: Innovation in the Treatment of NMSC: siRNA STP705 for SCC in situ
  • Presented by: Mark Steven Nestor, M.D., Ph.D.; Director, Center for Cosmetic Enhancement, Center for Clinical and Cosmetic Research in Aventura, Florida
  • The presentation will be available for viewing for one year via the conference website, starting at 2:45PM ET on Saturday, February 6, 2021
  • About STP705 
    Sirnaomics’ leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received IND approvals from both the US FDA and Chinese NMPA, including treatments for Liver cancer, non-melanoma skin cancer, and hypertrophic scar. STP705 has also received three Orphan Drug Designations from the US FDA for treatment of cholangiocarcinoma, primary sclerosing cholangitis and Hepatocellular Carcinoma. Preclinical animal models, as well as recent human tissue analysis from our isSCC study using STP705, have demonstrated statistically significant gene target knockdown as well as reduction in many tumor biomarkers that are common to multiple different tumor types. We have also witnessed in both our animal and human data improvement in T-cell penetration in multiple tumor types. These effects may lead to improved tumor response via oncogenic biomarker reduction and increase in T-cell penetration, which has the potential to enhance the activity of traditional chemotherapy and immune checkpoint inhibitor efficacies via T-cell enhancement. Based on the results of the STP705 Phase 2a trial, Sirnaomics intends to initiate a Phase 2b trial of STP705 in patients with isSCC, Bowen’s disease.

    Related posts

    Fundstrat Signs Agreement to Have MST Financial Distribute Research to Australia/New Zealand

    I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.

    February 5, 2021
    DRB Capital and Rightway Funding Agree to Resolve Pending Litigation

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    February 5, 2021

    About Sirnaomics, Inc. 
    Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a combined experience in the biopharmaceutical industry, spanning research and development, clinical development, regulatory affairs, and financial and business management in both the USA and China. The company is supported by funding from institutional investors and corporate partnerships. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology, anti-fibrotic, anti-viral, and metabolic therapeutics. Learn more at www.sirnaomics.com.

    Contact:

    Sirnaomics: 
    Michael Molyneaux, MD, MBA 
    Chief Medical Officer 
    Email: michaelmolyneaux@sirnaomics.com  

    Investors: 
    Stephanie Carrington 
    Tel: +1 646 277 1282  
    Email : Stephanie.Carrington@westwicke.com  

    Media: 
    Mark Corbae 
    Tel: +1 203 682 8288 
    Email: Mark.Corbae@westwicke.com  

    SOURCE: Sirnaomics, Inc.

    Related Links

    http://www.sirnaomics.com

    POPULAR NEWS

    • Eric Porat, Serial Entrepreneur, Expands Digital Empire

      Eric Porat, Serial Entrepreneur, Expands Digital Empire

      0 shares
      Share 0 Tweet 0
    • Tryp Technologies, Inc. announced the launch today of its TripDelivers restaurants & grocery services to open 36 markets in 21 States

      0 shares
      Share 0 Tweet 0
    • MINISO Launches Budding Pop Blind Box Collection, Delivering a Sweet Surprise to Every Customer

      0 shares
      Share 0 Tweet 0
    • Legal Team Led by Robert F. Kennedy, Jr. Sues New York State on Behalf of Families for Denying Lawful Medical Exemptions to School Children

      0 shares
      Share 0 Tweet 0
    • Delta Dental Of California And Its Affiliates Announce Additional $100 Million In Funding To Its COVID-19 Financial Assistance Loan Program

      0 shares
      Share 0 Tweet 0
    PRNewsCentre

    PRNewsCentre is a PR Publication website focused to provide Startups and SMEs a platform through which they can create a digital presence and build their brand identity

    Follow us on social media:

    Recent News

    • Labstat Welcomes Dr. Willie J. McKinney Jr. Ph.D., D.A.B.T
    • As Additional U.S. States Move Towards Legalization the Cannabis Industry Revenues Continue to Explode
    • Media Design Group Announces Dr. Squatch’s First Ever Super Bowl Ad

    Category

    • Art & Culture
    • Artificial Intelligence
    • Biotechnology
    • Blockchain
    • Business
    • Consumer Technology
    • Data Analytics
    • Entertainment
    • Environment
    • Fashion
    • Finance
    • Fintech
    • Fitness
    • Health
    • Internet Technology
    • Lifestyle
    • Manufacturing
    • Medical Equipment
    • National
    • Networks
    • News
    • Opinion
    • Pharmaceutical
    • Politics
    • Retail
    • Sports
    • Telecommunications
    • Transportation
    • Travel
    • Uncategorized

    Recent News

    Labstat Welcomes Dr. Willie J. McKinney Jr. Ph.D., D.A.B.T

    Labstat Welcomes Dr. Willie J. McKinney Jr. Ph.D., D.A.B.T

    February 5, 2021
    Phoenix Contact, Quectel e Ericsson conjuntamente desenvolvem o primeiro roteador 5G industrial para redes privadas

    As Additional U.S. States Move Towards Legalization the Cannabis Industry Revenues Continue to Explode

    February 5, 2021
    • About
    • Advertise
    • Careers

    Copyright © 2020 PRNewsCentre - All rights reserved

    No Result
    View All Result
    • Business
      • Business & Finance
      • Entertainment
      • General Business
      • Travel
      • Transportation
    • Internet
      • Blockchain
      • Data Analytics
      • Fintech
      • Internet Technology
      • Networks
    • Technology
      • Artificial Intelligence
      • Consumer Technology
      • Environment
      • Manufacturing
      • Telecommunications
    • Lifestyle
      • Entertainment
      • Fashion
      • Retail
      • Sports
      • Travel
    • Health
      • All Health
      • Biotechnology
      • Fitness
      • Pharmaceutical
      • Medical Equipment
    • Submit PR

    Copyright © 2020 PRNewsCentre - All rights reserved

    Login to your account below

    Forgotten Password?

    Fill the forms bellow to register

    All fields are required. Log In

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In